Elan's sets Tysabri pricing 22% above market forecasts: the wholesale cost per annum of a patient's treatment would now be $28,400
: "Irish drug company Elan Corp. (ELN) said Friday its multiple sclerosis drug Tysabri will have a wholesale price of $2,185 per 15-milliliter vial, which analysts say is nearly 21% above expectations.

The company has revised its pricing in line with that of MS treatments in general, which have risen in price between 10% and 27% since November 2004, a company spokeswoman told Dow Jones Newswires. .....the wholesale cost per annum of a patient's treatment would now be $28,400"